Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
C26H44NO6SNa
CAS Number:
Molecular Weight:
521.69
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12161900
MDL number:
description
anionic
Quality Level
assay
≥95.0% (TLC)
form
powder
mol wt
521.69 g/mol
CMC
4
HLB
20.1
application(s)
(Cell Biology, Drug formulation)
SMILES string
[H][C@@]12[C@]([C@](CC[C@@H](O)C3)(C)[C@]3([H])C[C@@H]2O)([H])CC[C@@]4(C)[C@@]1([H])CC[C@]4([H])[C@]([H])(C)CCC(NCCS(=O)([O-])=O)=O.[Na+]
InChI
1S/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17+,18-,19-,20+,21+,22+,24+,25+,26-/m1/s1
InChI key
BHTRKEVKTKCXOH-LBSADWJPSA-N
General description
Sodium tauroursodeoxycholate is a bile salt which is naturally present in the small bowel.
Application
Sodium tauroursodeoxycholate has been used in a study to assess whether ER stress is involved in palmitic acid upregulation (PA). It has also been used in a study to investigate its effect on Estradiol-17β-D-glucuronide (E-17G) induced cholestasis in female rats.
Storage Class
11 - Combustible Solids
wgk
WGK 2
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Structure-function analysis of the tertiary bile acid TUDCA for the resolution of endoplasmic reticulum stress in intestinal epithelial cells
Berger, E. and D. Haller
Biochemical and Biophysical Research Communications, 409, 6-6 (2011)
Masato Mochizuki et al.
PloS one, 13(8), e0202962-e0202962 (2018-08-28)
Cumulus-free in vitro maturation (IVM) provides a powerful tool to manipulate immature oocytes, but IVM oocytes lead to poor development after fertilization. Supplementation of the culture medium with tauroursodeoxycholic acid (TUDCA), a bile acid, has been reported to improve the
Laura Obici et al.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 19 Suppl 1, 34-36 (2012-05-04)
We designed a phase II, open-label study to evaluate the efficacy, tolerability, safety, and pharmacokinetics of orally doxycycline (100 mg BID) and tauroursodeoxycholic acid (TUDCA) (250 mg three times/day) administered continuously for 12 months. Primary endpoint is response rate defined